Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 10/20 | 0.45 |
| ▸ | DRD3 | P35462 | 10/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390935 | 0.95 | DRD2 (0.46) | HRH4DRD2DRD3CHRM3PDE4A | |
| SCHEMBL4401383 | 0.88 | HRH4 (0.45) | HRH4DRD2DRD3CHRM3PDE4A | |
| SCHEMBL392228 | 0.84 | DRD2 (0.56) | DRD2DRD3 | |
| SCHEMBL4398175 | 0.83 | DRD2 (0.46) | HRH4DRD2DRD3CHRM3PDE4A | |
| SCHEMBL4396559 | 0.80 | CHRM3 (0.40) | DRD2DRD3CHRM3PDE4APDE4B | |
| SCHEMBL4390618 | 0.80 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4390610 | 0.78 | DRD3 (0.41) | HRH4DRD2DRD3 | |
| SCHEMBL4396570 | 0.78 | DRD3 (0.40) | HRH4DRD2DRD3 | |
| SCHEMBL4400580 | 0.77 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL4396315 | 0.76 | CHRM3 (0.39) | HRH4DRD2DRD3CHRM3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202868-B2 | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2012-06-19 | — | — | US | disclosed |
| EP-1778684-B1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D<sb>3</sb> RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-1778684-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&lt;sb&gt;3&lt;/sb&gt; RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015842-A1 | 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264437-A1 | 4-Piperazinyl-Pyrimidine Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ADRA1D, ADRA1A, ADRA2A | HRH4 87/4885DRD2 6/4885DRD3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.